english.prescrire.org > Spotlight > 100 most recent > Janus kinase inhibitors: higher incidence of serious adverse effects and death than with TNF-alpha inhibitors

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Janus kinase inhibitors: higher incidence of serious adverse effects and death than with TNF-alpha inhibitors

 Adverse Effects  The increased incidence of serious adverse effects associated with tofacitinib and baricitinib, and probably also the three other JAK inhibitors used in chronic inflammatory diseases, raises questions about the harm-benefit balance of drugs of this class.
Full article (1 page) available for download by subscribers

The EMA recommends using the Janus kinase (JAK) inhibitors abrocitinib, baricitinib, filgotinib, tofacitinib and upadacitinib, authorised mainly for chronic inflammatory diseases, only as a last resort, in certain patients.

©Prescrire 1 May 2023

Source: "Janus kinase inhibitors: higher incidence of serious adverse effects and death than with TNF-alpha inhibitors" Prescrire International 2023; 32 (248): 131. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >